(Lung Cancer) Is Datopotamab Deruxtecan Effective?
(Lung Cancer) Is Datopotamab Deruxtecan Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
(Lung Cancer) Is Datopotamab Deruxtecan Effective?
- July 10, 2023
- 1 min read
On July 3, 2023, Daiichi Sankyo and AstraZeneca announced results from the TROPION-Lung01 Phase III clinical trial evaluating TROP2 antibody drug Datopotamab Deruxtecan (Dato-DXd) as second- or third-line treatment for non-small cell lung cancer.
The TROPION-Lung01 Phase III clinical trial was a global trial that enrolled previously treated advanced or metastatic non-small cell lung cancer patients (approximately 600), divided into the Dato-DXd group and the Docetaxel group.
In this announcement, the primary endpoint progression-free survival showed significant improvement in the Dato-DXd group compared to the other group. The interim analysis results for the other primary endpoint, overall survival, showed an initial trend toward improvement in the Dato-DXd group; however, there was no statistically significant difference. The data will continue to be evaluated until the final analysis.
Regarding safety, this trial showed trends consistent with other studies using Dato-DXd. The drug is associated with interstitial lung disease, most of which were grade 1 or 2, though grade 5 adverse events with confirmed patient deaths were also observed.
Detailed results of this study will be presented at a future academic conference.
Source: https://www.daiichisankyo.co.jp/files/news/pressrelease/pdf/202307/20230703_J.pdf
-
Investigational Drugs
(Lung Cancer) Topotecan and Topotecan + Berzosertib Treatment Results in Phase II Clinical Trial. (Lung Cancer) Is Trastuzumab deruxtecan Effective for HER2-Mutant Non-Small Cell Lung Cancer? (Lung Cancer) Is the Anti-B7-H3 Antibody Drug DS-7300 Effective?
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free (initial direction only; further services are quoted separately); an advisor will help you clarify the next steps.